ORPOF News and Press, OSE Immunotherapeutics SA From 07/04/23

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the United States Patent and Trademark Office has granted a new patent protecting Tedopi®, a therapeutic cancer vaccine treating HLA-A2 positive patients after secondary resistance to PD-...

A €1.5 million funding from “Bpifrance – Direction Régionale de Nantes” as part of an “R&D Innovation Loan” program. Development of a companion diagnostic test to identify HLA-A2 positive non-small cell lung cancer (NSCLC) patients el...

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody Engineering & Therapeutics Europe 2023 Conference in Amsterdam, Netherlands (June 7), at...

Tedopi ® is the Company’s Most Advanced Product in Clinical Development ATALANTE-1, a Phase 3 clinical trial with positive results comparing Tedopi ® to chemotherapy in non-small cell lung cancer (NSCLC) after failure to immunotherapy: New data on prog...

Financial highlights 2022 total turnover of €18 million driven by strategic partnerships with pharmaceutical companies. €25.6 million available cash as of December 31 st 2022, including the drawdown of the second tranche of €10 million under a fina...

At the 2023 American Association for Cancer Research (AACR) Annual Meeting CLEC-1 inhibitory myeloid checkpoint blockade enhances antitumor responses and tumor phagocytosis by macrophages. TRIM21 has been identified by OSE Immunotherapeutics in collaboration with Dr Elise Chif...

At the 2023 American Association for Cancer Research Annual Meeting BI 765063, first-in-class SIRPα inhibitor on the SIRPα/CD47 myeloid pathway in advanced solid tumors. OSE-127, monoclonal immunomodulatory antibody targeting the CD127 receptor, the alpha chain o...

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating tumor specific T-cells, in phase 3 in monotherapy in advanced or metastatic non-small ce...

OSE Immunotherapeutics SA press release ( OTC:ORPOF ): 1H GAAP EPS of -€0.11. Revenue of €16.05M (+78.7% Y/Y). As of June 30, 2022, available cash amounted to €31M, giving a financial visibility until Q3 2023. For further details see: OS...